SPRY vs. MIST

In the year-to-date period, SPRY achieves a 46.82% return, which is significantly higher than MIST's -32.63% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Silverback Therapeutics Inc (SPRY) and Milestone Pharmaceuticals Inc. (MIST). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current SPRY Sharpe Ratio is 1.12, which is higher than the MIST Sharpe Ratio of 0.02. The chart below compares the historical Sharpe Ratios of SPRY and MIST, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither SPRY nor MIST has paid dividends to shareholders.

The maximum SPRY drawdown since its inception was -95.20%, roughly equal to the maximum MIST drawdown of -97.59%. Use the drawdown chart below to compare losses from any high point for SPRY and MIST.

The current volatility for Silverback Therapeutics Inc (SPRY) is 17.80%, while Milestone Pharmaceuticals Inc. (MIST) has a volatility of 24.62%. This indicates that SPRY experiences smaller price fluctuations and is considered to be less risky than MIST based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Silverback Therapeutics Inc and Milestone Pharmaceuticals Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.